JP2005508840A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2005508840A5 JP2005508840A5 JP2002576895A JP2002576895A JP2005508840A5 JP 2005508840 A5 JP2005508840 A5 JP 2005508840A5 JP 2002576895 A JP2002576895 A JP 2002576895A JP 2002576895 A JP2002576895 A JP 2002576895A JP 2005508840 A5 JP2005508840 A5 JP 2005508840A5
- Authority
- JP
- Japan
- Prior art keywords
- compound
- acetylcysteine
- pharmaceutically acceptable
- combination
- agent
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 150000001875 compounds Chemical class 0.000 claims 24
- 238000000034 method Methods 0.000 claims 21
- PWKSKIMOESPYIA-BYPYZUCNSA-N L-N-acetyl-Cysteine Chemical compound CC(=O)N[C@@H](CS)C(O)=O PWKSKIMOESPYIA-BYPYZUCNSA-N 0.000 claims 19
- 229960004308 acetylcysteine Drugs 0.000 claims 19
- RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 claims 18
- 239000003814 drug Substances 0.000 claims 15
- 229940124597 therapeutic agent Drugs 0.000 claims 15
- 239000008194 pharmaceutical composition Substances 0.000 claims 12
- 150000003839 salts Chemical class 0.000 claims 12
- 229960005489 paracetamol Drugs 0.000 claims 9
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 claims 8
- 230000001225 therapeutic effect Effects 0.000 claims 7
- 230000000202 analgesic effect Effects 0.000 claims 6
- 239000003242 anti bacterial agent Substances 0.000 claims 6
- 230000001754 anti-pyretic effect Effects 0.000 claims 6
- 239000002221 antipyretic Substances 0.000 claims 6
- 239000003443 antiviral agent Substances 0.000 claims 6
- 230000003115 biocidal effect Effects 0.000 claims 6
- 108010024636 Glutathione Proteins 0.000 claims 4
- 229940124522 antiretrovirals Drugs 0.000 claims 4
- 239000003903 antiretrovirus agent Substances 0.000 claims 4
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 claims 4
- 235000018417 cysteine Nutrition 0.000 claims 4
- 229960003180 glutathione Drugs 0.000 claims 4
- 230000036542 oxidative stress Effects 0.000 claims 4
- 231100000419 toxicity Toxicity 0.000 claims 3
- 230000001988 toxicity Effects 0.000 claims 3
- 241000124008 Mammalia Species 0.000 claims 2
- 239000003937 drug carrier Substances 0.000 claims 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims 2
- 231100000331 toxic Toxicity 0.000 claims 2
- 230000002588 toxic effect Effects 0.000 claims 2
- 241000725303 Human immunodeficiency virus Species 0.000 claims 1
- 206010037660 Pyrexia Diseases 0.000 claims 1
- 239000002872 contrast media Substances 0.000 claims 1
- 230000009984 peri-natal effect Effects 0.000 claims 1
- 239000008177 pharmaceutical agent Substances 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US28060001P | 2001-03-30 | 2001-03-30 | |
| US09/833,228 US6566401B2 (en) | 2001-03-30 | 2001-04-11 | N-acetylcysteine compositions and methods for the treatment and prevention of drug toxicity |
| PCT/US2002/009442 WO2002078627A2 (en) | 2001-03-30 | 2002-03-28 | N-acetylcysteine compositions and methods for the treatment and prevention of drug toxicity |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2011168224A Division JP2011225610A (ja) | 2001-03-30 | 2011-08-01 | Ｎ−アセチルシステイン組成物及び薬剤毒性治療または防止方法 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2005508840A JP2005508840A (ja) | 2005-04-07 |
| JP2005508840A5 true JP2005508840A5 (enExample) | 2005-12-22 |
Family
ID=26960383
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2002576895A Pending JP2005508840A (ja) | 2001-03-30 | 2002-03-28 | Ｎ−アセチルシステイン組成物及び薬剤毒性治療または防止方法 |
| JP2011168224A Pending JP2011225610A (ja) | 2001-03-30 | 2011-08-01 | Ｎ−アセチルシステイン組成物及び薬剤毒性治療または防止方法 |
| JP2014205506A Pending JP2015078185A (ja) | 2001-03-30 | 2014-10-06 | Ｎ−アセチルシステイン組成物及び薬剤毒性治療または防止方法 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2011168224A Pending JP2011225610A (ja) | 2001-03-30 | 2011-08-01 | Ｎ−アセチルシステイン組成物及び薬剤毒性治療または防止方法 |
| JP2014205506A Pending JP2015078185A (ja) | 2001-03-30 | 2014-10-06 | Ｎ−アセチルシステイン組成物及び薬剤毒性治療または防止方法 |
Country Status (13)
| Country | Link |
|---|---|
| US (2) | US6566401B2 (enExample) |
| EP (1) | EP1379232B1 (enExample) |
| JP (3) | JP2005508840A (enExample) |
| CN (1) | CN100464743C (enExample) |
| AU (1) | AU2002255942B2 (enExample) |
| BR (1) | BR0208563A (enExample) |
| CA (1) | CA2442168C (enExample) |
| ES (1) | ES2550094T3 (enExample) |
| IL (2) | IL158181A0 (enExample) |
| MX (1) | MXPA03008904A (enExample) |
| NZ (1) | NZ528478A (enExample) |
| RU (1) | RU2291689C2 (enExample) |
| WO (1) | WO2002078627A2 (enExample) |
Families Citing this family (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7662863B2 (en) * | 2003-06-09 | 2010-02-16 | Alan Andrews | Therapeutic agent for the use in reducing alcohol intoxication and reducing or eliminating the negative side effects associated with alcohol ingestion |
| PL2982372T3 (pl) | 2005-04-05 | 2020-12-28 | Yale University | Środki modulujące stężenie glutaminianu stosowane w leczeniu zaburzeń psychicznych |
| US8993627B2 (en) * | 2005-04-21 | 2015-03-31 | Sentient Lifesciences, Inc. | N-acetylcysteine amide (NAC amide) for the treatment of diseases and conditions associated with oxidative stress |
| US8148356B2 (en) * | 2005-08-24 | 2012-04-03 | Cumberland Pharmaceuticals, Inc. | Acetylcysteine composition and uses therefor |
| RU2302236C2 (ru) * | 2005-09-09 | 2007-07-10 | Государственное учреждение научно-исследовательский институт Гриппа Российской академии медицинских наук (ГУ НИИ Гриппа РАМН) | Средство, обладающее антигипоксической и цитопротекторной активностями, используемое для снижения токсичности ремантадина при лечении гриппозной инфекции |
| US20070098790A1 (en) * | 2005-10-31 | 2007-05-03 | David Jiang | Nutritional supplement for the enhancement of the health of the liver |
| US20080139654A1 (en) * | 2006-12-09 | 2008-06-12 | Eric Mott Soderling | Acetaminophen compositions having minimized side effects including reduced hepatotoxicity |
| BRPI0912716A2 (pt) * | 2008-05-13 | 2015-10-13 | Genmedica Therapeutics Sl | composto. |
| JP2012520343A (ja) * | 2009-03-16 | 2012-09-06 | ジェンメディカ・セラピューティックス・ソシエダッド・リミターダ | 代謝障害治療のための併用療法 |
| AU2010224866C1 (en) * | 2009-03-16 | 2015-01-15 | Genmedica Therapeutics Sl | Anti-inflammatory and antioxidant conjugates useful for treating metabolic disorders |
| AU2010248758A1 (en) * | 2009-05-15 | 2011-11-24 | Intermune, Inc. | Methods of treating HIV patients with anti-fibrotics |
| WO2011006097A2 (en) * | 2009-07-10 | 2011-01-13 | The Brigham And Women's Hospital, Inc. | Methods For Treating Toxicity |
| JP2012533559A (ja) * | 2009-07-15 | 2012-12-27 | ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティ | アセトアミノフェンの治療効果を改善するためのｎ−アセチルシステイン組成物および方法 |
| DE102011006425A1 (de) | 2010-03-31 | 2011-10-06 | Awd.Pharma Gmbh & Co. Kg | Pharmazeutische Zubereitung und deren Verwendung |
| US8466197B2 (en) | 2010-12-14 | 2013-06-18 | Genmedica Therapeutics Sl | Thiocarbonates as anti-inflammatory and antioxidant compounds useful for treating metabolic disorders |
| US20140135396A1 (en) * | 2011-07-05 | 2014-05-15 | Beth Israel Deaconess Medical Center, Inc. | Treatment of Acetaminophen-Induced Liver Damage by the Administration of Modulators of Nitric Oxide |
| US8747894B2 (en) | 2012-05-08 | 2014-06-10 | Alpex Pharma S.A. | Effervescent compositions containing N-acetylcysteine |
| WO2013175479A1 (en) | 2012-05-24 | 2013-11-28 | Hadasit Medical Research Services And Development Ltd. | Compositions comprising isosilybin b for amelioration and prevention of drug- induced toxicity |
| TWI734665B (zh) | 2013-12-24 | 2021-08-01 | 維吉尼亞聯邦大學 | 氧化膽固醇硫酸鹽（ｏｃｓ）之用途 |
| CA2974011A1 (en) * | 2015-01-27 | 2016-08-04 | Florengale, Llc | Healing topical composition |
| WO2016191743A1 (en) * | 2015-05-27 | 2016-12-01 | University Of Pittsburgh-Of The Commonwealth System Of Higher Education | Compositions and methods for reducing the risk of post-imaging pancreatitis |
| MX389285B (es) | 2015-05-28 | 2025-03-20 | Baylor College Medicine | Beneficios de la suplementación con n-acetilcisteína y glicina para mejorar los niveles de glutatión. |
| EP3842040B1 (en) * | 2016-01-11 | 2022-03-09 | Egetis Therapeutics AB | Methods and formulations for treatment of and/or protection against acute liver failure and other hepatotoxic conditions |
| PL3411047T3 (pl) | 2016-02-04 | 2021-11-15 | Czap Research And Development, Llc | Nośniki kompleksów inkluzyjnych cyklodekstryn o kontrolowanym uwalnianiu i stratyfikowane |
| EP3554491B1 (en) | 2016-12-15 | 2023-02-15 | Zambon S.p.A. | N-acetylcysteine for use as antibacterial agent |
| WO2018139842A1 (ko) * | 2017-01-24 | 2018-08-02 | 주식회사 우성제약 | 아세트아미노펜을 함유하는 주사제 조성물 |
| WO2020129509A1 (ja) * | 2018-12-21 | 2020-06-25 | 富士フイルム株式会社 | 光毒性または光アレルギーの測定方法および上記測定方法において使用するための試薬 |
| US11590090B2 (en) | 2019-09-14 | 2023-02-28 | Anzen Pharmaceuticals, LLC | Acetaminophen formulation with protection against toxic effects of overdose |
| GB2588172B (en) * | 2019-10-11 | 2023-05-24 | Blackhawk Partners Ltd | A pharmaceutical composition comprising cannabinoid |
| CN113288890B (zh) * | 2021-06-21 | 2022-02-22 | 南方医科大学南方医院 | N-乙酰-l-半胱氨酸在制备预防和/或治疗运动损伤的药物中的应用 |
| US12357667B2 (en) | 2021-07-28 | 2025-07-15 | Pono Lifestyle, Llc | Nutraceutical formulations to prevent, treat, and inhibit excess cytokines, SARS-CoV-2 spike proteins, and mRNA vaccine spike proteins |
| EP4238559A1 (en) | 2022-03-04 | 2023-09-06 | Centre Hospitalier Universitaire de Caen Normandie | Combinations of acetaminophen and n-acetyl cysteine for the treatment of pain and fever |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US547457A (en) * | 1895-10-08 | Trolley-track | ||
| IT1141406B (it) * | 1980-04-01 | 1986-10-01 | Dob Far Spa | Sali della cefapirina con aminoacidi |
| FR2519988B1 (fr) * | 1982-01-20 | 1985-06-14 | Refarmed Sa | Derives thioliques de l'erythromycine a activite therapeutique, procede de preparation et produits pharmaceutiques dans lesquels ils apparaissent |
| DE3616923A1 (de) | 1986-05-20 | 1987-11-26 | Nattermann A & Cie | Neue pharmazeutische verwendung von 2-phenyl-1,2-benzisoselenazol-3(2h)-on |
| CA1339256C (en) * | 1989-01-26 | 1997-08-12 | Wulf Droge | Treatment of diseases associated with hiv-infections |
| IT1248995B (it) * | 1990-06-26 | 1995-02-11 | Italfarmaco Spa | Composizioni farmaceutiche a base di sali ferrosi |
| US5474757A (en) * | 1992-10-16 | 1995-12-12 | Rutgers University | Prevention of acetaminophen overdose toxicity with organosulfur compounds |
| US5762922A (en) * | 1994-01-31 | 1998-06-09 | Ludwig Institute For Cancer Research | Antioxidants and intracellular gluthathione raising agents for therapeutic treatments |
| US5475757A (en) * | 1994-06-07 | 1995-12-12 | At&T Corp. | Secure data transmission method |
| WO1996019489A1 (en) * | 1994-12-19 | 1996-06-27 | Russinsky Limited | Compounds |
| US5750493A (en) * | 1995-08-30 | 1998-05-12 | Raymond F. Schinazi | Method to improve the biological and antiviral activity of protease inhibitors |
| FR2744917B1 (fr) | 1996-02-16 | 1998-04-10 | Kouchner Gerard | Composition therapeutique a base d'acetaminophene |
| US5837729A (en) * | 1996-04-26 | 1998-11-17 | Metatron, Inc. | Methods for treating and preventing HIV infection using acetaminophen and derivatives thereof |
| US5962421A (en) * | 1996-05-16 | 1999-10-05 | Zambon, S.A. | Pharmacological association between N-acetylcysteine and levulose for preventing cellular death and related diseases |
| CA2294247C (en) * | 1997-07-01 | 2004-10-26 | Atherogenics, Inc. | Antioxidant enhancement of therapy for hyperproliferative conditions |
| IL143701A0 (en) * | 1999-01-04 | 2002-04-21 | Ml Lab Plc | Gene therapy-1 |
| IT1312086B1 (it) * | 1999-04-21 | 2002-04-04 | Zambon Spa | Uso della nac per la preparazione di un medicamento adatto allasomministrazione endovenosa per la prevenzione dello stress |
| DE10112325A1 (de) | 2001-03-13 | 2002-10-02 | Fresenius Kabi De Gmbh | Lagerstabile Fertiginfusionslösungen des Paracetamols |
-
2001
- 2001-04-11 US US09/833,228 patent/US6566401B2/en not_active Expired - Lifetime
-
2002
- 2002-03-28 RU RU2003131876/15A patent/RU2291689C2/ru not_active IP Right Cessation
- 2002-03-28 JP JP2002576895A patent/JP2005508840A/ja active Pending
- 2002-03-28 CN CNB028077334A patent/CN100464743C/zh not_active Expired - Fee Related
- 2002-03-28 ES ES02725376.4T patent/ES2550094T3/es not_active Expired - Lifetime
- 2002-03-28 CA CA2442168A patent/CA2442168C/en not_active Expired - Lifetime
- 2002-03-28 MX MXPA03008904A patent/MXPA03008904A/es active IP Right Grant
- 2002-03-28 WO PCT/US2002/009442 patent/WO2002078627A2/en not_active Ceased
- 2002-03-28 EP EP02725376.4A patent/EP1379232B1/en not_active Revoked
- 2002-03-28 IL IL15818102A patent/IL158181A0/xx unknown
- 2002-03-28 AU AU2002255942A patent/AU2002255942B2/en not_active Expired
- 2002-03-28 NZ NZ528478A patent/NZ528478A/en not_active IP Right Cessation
- 2002-03-28 BR BRPI0208563-1A patent/BR0208563A/pt not_active IP Right Cessation
- 2002-11-04 US US10/287,175 patent/US7723389B2/en not_active Expired - Fee Related
-
2003
- 2003-09-30 IL IL158181A patent/IL158181A/en active IP Right Grant
-
2011
- 2011-08-01 JP JP2011168224A patent/JP2011225610A/ja active Pending
-
2014
- 2014-10-06 JP JP2014205506A patent/JP2015078185A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2005508840A5 (enExample) | ||
| RU2003131876A (ru) | Композиции n-ацетилцистеина и способы лечения и профилактики токсичности лекарственных средств | |
| JP2572768B2 (ja) | レボドパメチルエステルを有効成分とするパ−キンソン病治療剤 | |
| WO2004002999A3 (en) | Modified 2' and 3' -nucleoside produgs for treating flaviridae infections | |
| KR950703951A (ko) | 광학적으로 순수한 r-케토로락을 포함하는 조성물과 무통과 해열치료에 이를 사용하는 방법(antipyretic and analgesic methods and compositions containing optically pure r-ketorolac) | |
| WO2005065069A3 (en) | Pharmaceutical methods, dosing regimes and dosage forms for the treatment of alzheimer's disease | |
| CY1111088T1 (el) | Θεραπευτικη φαρμακοτεχνικη μορφη για χορηγηση τολτεροδινης με ελεγχομενη απελευθερωση | |
| ATE350040T1 (de) | Stabilisierte pharmazeutische zusammensetzung enthaltend einen nichtsteroiden entzündungshemmenden wirkstoff und prostaglandin | |
| JP2008521784A5 (enExample) | ||
| RU98111594A (ru) | Фармацевтические композиции, включающие флурбипрофен | |
| IL300151A (en) | Combinations for the treatment of cancer | |
| RU2008137604A (ru) | Применение деферипрона и способ лечения и/или профилактики атаксии фридрейха, возникающей вследствие внутриклеточного нарушения обмена железа | |
| JP2006516571A5 (enExample) | ||
| JP2002528502A5 (enExample) | ||
| RU2008119454A (ru) | Лекарственное средство для защиты моторного нейрона у пациентов с боковым амиотрофическим склерозом | |
| JP5403935B2 (ja) | 経口用の慢性疼痛予防または治療剤 | |
| CL2024003616A1 (es) | Composición farmacéutica oral y uso para la terapia de enfermedades pulmonares intersticiales fibrosantes progresivas. | |
| US6281222B1 (en) | Compositions and method for treatment of acetaminophen intoxication | |
| AR022116A1 (es) | Terapia de combinacion para el vhc por induccion de ribavirina - interferon alfa | |
| JP2006104186A (ja) | 感冒用医薬組成物 | |
| BR0211855A (pt) | Medicamento e método para tratamento e melhoria da qualidade restauradora do sono | |
| RU2006139819A (ru) | Применение симетикона для предрасположенных к запорам пациентов | |
| BRPI0410374A (pt) | composição farmacêutica que compreende valsartano | |
| Cailleteau | Ketoprofen in dentistry: a pharmacologic review | |
| JPWO2020146666A5 (enExample) |